Global Primary Sclerosing Cholangitis Treatment Market Growth (Status and Outlook) 2022-2028

January 2021 | 124 pages | ID: GA5026FD127EEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Primary Sclerosing Cholangitis Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Primary Sclerosing Cholangitis Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Primary Sclerosing Cholangitis Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Primary Sclerosing Cholangitis Treatment market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Primary Sclerosing Cholangitis Treatment market, reaching US$ million by the year 2028. As for the Europe Primary Sclerosing Cholangitis Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Primary Sclerosing Cholangitis Treatment players cover Allergan, Glenmark, Impax Laboratories, and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Sclerosing Cholangitis Treatment market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

• Liver Transplantation Operation
• UDCA Drugs
• PSC Drugs

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

• Hospital
• Clinics
• Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

• Allergan
• Glenmark
• Impax Laboratories
• Mylan
• Teva Pharmaceuticals
• Dr. Falk Pharma
• Daewoong Pharmaceutical
• Epic Pharma
• Mitsubishi Tanabe Pharma
• Lannett
• Bruschettini
• Shanghai Pharma
• Grindeks
• Acorda Therapeutics
• Gilead Sciences
• Intercept Pharmaceuticals
• Shire Plc
• NGM Biopharmaceuticals
• Conatus Pharmaceuticals
• Durect Corporation
• Sirnaomics
• Shenzhen HighTide Biopharmaceuticals

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Primary Sclerosing Cholangitis Treatment Market Size 2017-2028
  2.1.2 Primary Sclerosing Cholangitis Treatment Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Primary Sclerosing Cholangitis Treatment Segment by Type
  2.2.1 Liver Transplantation Operation
  2.2.2 UDCA Drugs
  2.2.3 PSC Drugs
2.3 Primary Sclerosing Cholangitis Treatment Market Size by Type
  2.3.1 Primary Sclerosing Cholangitis Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028)
  2.3.2 Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
2.4 Primary Sclerosing Cholangitis Treatment Segment by Application
  2.4.1 Hospital
  2.4.2 Clinics
  2.4.3 Other
2.5 Primary Sclerosing Cholangitis Treatment Market Size by Application
  2.5.1 Primary Sclerosing Cholangitis Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028)
  2.5.2 Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

3 PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET SIZE BY PLAYER

3.1 Primary Sclerosing Cholangitis Treatment Market Size Market Share by Players
  3.1.1 Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2020-2022)
  3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2020-2022)
3.2 Global Primary Sclerosing Cholangitis Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 PRIMARY SCLEROSING CHOLANGITIS TREATMENT BY REGIONS

4.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions (2017-2022)
4.2 Americas Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)
4.3 APAC Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)
4.4 Europe Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)
4.5 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)

5 AMERICAS

5.1 Americas Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
5.2 Americas Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
5.3 Americas Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022)
6.2 APAC Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
6.3 APAC Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Primary Sclerosing Cholangitis Treatment by Country (2017-2022)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment by Region (2017-2022)
8.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
8.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET FORECAST

10.1 Global Primary Sclerosing Cholangitis Treatment Forecast by Regions (2023-2028)
  10.1.1 Global Primary Sclerosing Cholangitis Treatment Forecast by Regions (2023-2028)
  10.1.2 Americas Primary Sclerosing Cholangitis Treatment Forecast
  10.1.3 APAC Primary Sclerosing Cholangitis Treatment Forecast
  10.1.4 Europe Primary Sclerosing Cholangitis Treatment Forecast
  10.1.5 Middle East & Africa Primary Sclerosing Cholangitis Treatment Forecast
10.2 Americas Primary Sclerosing Cholangitis Treatment Forecast by Country (2023-2028)
  10.2.1 United States Primary Sclerosing Cholangitis Treatment Market Forecast
  10.2.2 Canada Primary Sclerosing Cholangitis Treatment Market Forecast
  10.2.3 Mexico Primary Sclerosing Cholangitis Treatment Market Forecast
  10.2.4 Brazil Primary Sclerosing Cholangitis Treatment Market Forecast
10.3 APAC Primary Sclerosing Cholangitis Treatment Forecast by Region (2023-2028)
  10.3.1 China Primary Sclerosing Cholangitis Treatment Market Forecast
  10.3.2 Japan Primary Sclerosing Cholangitis Treatment Market Forecast
  10.3.3 Korea Primary Sclerosing Cholangitis Treatment Market Forecast
  10.3.4 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Forecast
  10.3.5 India Primary Sclerosing Cholangitis Treatment Market Forecast
  10.3.6 Australia Primary Sclerosing Cholangitis Treatment Market Forecast
10.4 Europe Primary Sclerosing Cholangitis Treatment Forecast by Country (2023-2028)
  10.4.1 Germany Primary Sclerosing Cholangitis Treatment Market Forecast
  10.4.2 France Primary Sclerosing Cholangitis Treatment Market Forecast
  10.4.3 UK Primary Sclerosing Cholangitis Treatment Market Forecast
  10.4.4 Italy Primary Sclerosing Cholangitis Treatment Market Forecast
  10.4.5 Russia Primary Sclerosing Cholangitis Treatment Market Forecast
10.5 Middle East & Africa Primary Sclerosing Cholangitis Treatment Forecast by Region (2023-2028)
  10.5.1 Egypt Primary Sclerosing Cholangitis Treatment Market Forecast
  10.5.2 South Africa Primary Sclerosing Cholangitis Treatment Market Forecast
  10.5.3 Israel Primary Sclerosing Cholangitis Treatment Market Forecast
  10.5.4 Turkey Primary Sclerosing Cholangitis Treatment Market Forecast
  10.5.5 GCC Countries Primary Sclerosing Cholangitis Treatment Market Forecast
10.6 Global Primary Sclerosing Cholangitis Treatment Forecast by Type (2023-2028)
10.7 Global Primary Sclerosing Cholangitis Treatment Forecast by Application (2023-2028)

11 KEY PLAYERS ANALYSIS

11.1 Allergan
  11.1.1 Allergan Company Information
  11.1.2 Allergan Primary Sclerosing Cholangitis Treatment Product Offered
  11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.1.4 Allergan Main Business Overview
  11.1.5 Allergan Latest Developments
11.2 Glenmark
  11.2.1 Glenmark Company Information
  11.2.2 Glenmark Primary Sclerosing Cholangitis Treatment Product Offered
  11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.2.4 Glenmark Main Business Overview
  11.2.5 Glenmark Latest Developments
11.3 Impax Laboratories
  11.3.1 Impax Laboratories Company Information
  11.3.2 Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Offered
  11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.3.4 Impax Laboratories Main Business Overview
  11.3.5 Impax Laboratories Latest Developments
11.4 Mylan
  11.4.1 Mylan Company Information
  11.4.2 Mylan Primary Sclerosing Cholangitis Treatment Product Offered
  11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.4.4 Mylan Main Business Overview
  11.4.5 Mylan Latest Developments
11.5 Teva Pharmaceuticals
  11.5.1 Teva Pharmaceuticals Company Information
  11.5.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
  11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.5.4 Teva Pharmaceuticals Main Business Overview
  11.5.5 Teva Pharmaceuticals Latest Developments
11.6 Dr. Falk Pharma
  11.6.1 Dr. Falk Pharma Company Information
  11.6.2 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Offered
  11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.6.4 Dr. Falk Pharma Main Business Overview
  11.6.5 Dr. Falk Pharma Latest Developments
11.7 Daewoong Pharmaceutical
  11.7.1 Daewoong Pharmaceutical Company Information
  11.7.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Offered
  11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.7.4 Daewoong Pharmaceutical Main Business Overview
  11.7.5 Daewoong Pharmaceutical Latest Developments
11.8 Epic Pharma
  11.8.1 Epic Pharma Company Information
  11.8.2 Epic Pharma Primary Sclerosing Cholangitis Treatment Product Offered
  11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.8.4 Epic Pharma Main Business Overview
  11.8.5 Epic Pharma Latest Developments
11.9 Mitsubishi Tanabe Pharma
  11.9.1 Mitsubishi Tanabe Pharma Company Information
  11.9.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Offered
  11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.9.4 Mitsubishi Tanabe Pharma Main Business Overview
  11.9.5 Mitsubishi Tanabe Pharma Latest Developments
11.10 Lannett
  11.10.1 Lannett Company Information
  11.10.2 Lannett Primary Sclerosing Cholangitis Treatment Product Offered
  11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.10.4 Lannett Main Business Overview
  11.10.5 Lannett Latest Developments
11.11 Bruschettini
  11.11.1 Bruschettini Company Information
  11.11.2 Bruschettini Primary Sclerosing Cholangitis Treatment Product Offered
  11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.11.4 Bruschettini Main Business Overview
  11.11.5 Bruschettini Latest Developments
11.12 Shanghai Pharma
  11.12.1 Shanghai Pharma Company Information
  11.12.2 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Offered
  11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.12.4 Shanghai Pharma Main Business Overview
  11.12.5 Shanghai Pharma Latest Developments
11.13 Grindeks
  11.13.1 Grindeks Company Information
  11.13.2 Grindeks Primary Sclerosing Cholangitis Treatment Product Offered
  11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.13.4 Grindeks Main Business Overview
  11.13.5 Grindeks Latest Developments
11.14 Acorda Therapeutics
  11.14.1 Acorda Therapeutics Company Information
  11.14.2 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product Offered
  11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.14.4 Acorda Therapeutics Main Business Overview
  11.14.5 Acorda Therapeutics Latest Developments
11.15 Gilead Sciences
  11.15.1 Gilead Sciences Company Information
  11.15.2 Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Offered
  11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.15.4 Gilead Sciences Main Business Overview
  11.15.5 Gilead Sciences Latest Developments
11.16 Intercept Pharmaceuticals
  11.16.1 Intercept Pharmaceuticals Company Information
  11.16.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
  11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.16.4 Intercept Pharmaceuticals Main Business Overview
  11.16.5 Intercept Pharmaceuticals Latest Developments
11.17 Shire Plc
  11.17.1 Shire Plc Company Information
  11.17.2 Shire Plc Primary Sclerosing Cholangitis Treatment Product Offered
  11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.17.4 Shire Plc Main Business Overview
  11.17.5 Shire Plc Latest Developments
11.18 NGM Biopharmaceuticals
  11.18.1 NGM Biopharmaceuticals Company Information
  11.18.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
  11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.18.4 NGM Biopharmaceuticals Main Business Overview
  11.18.5 NGM Biopharmaceuticals Latest Developments
11.19 Conatus Pharmaceuticals
  11.19.1 Conatus Pharmaceuticals Company Information
  11.19.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
  11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.19.4 Conatus Pharmaceuticals Main Business Overview
  11.19.5 Conatus Pharmaceuticals Latest Developments
11.20 Durect Corporation
  11.20.1 Durect Corporation Company Information
  11.20.2 Durect Corporation Primary Sclerosing Cholangitis Treatment Product Offered
  11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.20.4 Durect Corporation Main Business Overview
  11.20.5 Durect Corporation Latest Developments
11.21 Sirnaomics
  11.21.1 Sirnaomics Company Information
  11.21.2 Sirnaomics Primary Sclerosing Cholangitis Treatment Product Offered
  11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.21.4 Sirnaomics Main Business Overview
  11.21.5 Sirnaomics Latest Developments
11.22 Shenzhen HighTide Biopharmaceuticals
  11.22.1 Shenzhen HighTide Biopharmaceuticals Company Information
  11.22.2 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
  11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
  11.22.4 Shenzhen HighTide Biopharmaceuticals Main Business Overview
  11.22.5 Shenzhen HighTide Biopharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Primary Sclerosing Cholangitis Treatment Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Liver Transplantation Operation
Table 3. Major Players of UDCA Drugs
Table 4. Major Players of PSC Drugs
Table 5. Primary Sclerosing Cholangitis Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
Table 8. Primary Sclerosing Cholangitis Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 9. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 10. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)
Table 11. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2020-2022) & ($ Millions)
Table 12. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Player (2020-2022)
Table 13. Primary Sclerosing Cholangitis Treatment Key Players Head office and Products Offered
Table 14. Primary Sclerosing Cholangitis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions 2017-2022 & ($ Millions)
Table 18. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Regions (2017-2022)
Table 19. Americas Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & ($ Millions)
Table 20. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Country (2017-2022)
Table 21. Americas Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 22. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
Table 23. Americas Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 24. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)
Table 25. APAC Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & ($ Millions)
Table 26. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region (2017-2022)
Table 27. APAC Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 28. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
Table 29. APAC Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 30. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)
Table 31. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & ($ Millions)
Table 32. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Country (2017-2022)
Table 33. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 34. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
Table 35. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 36. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)
Table 37. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & ($ Millions)
Table 38. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region (2017-2022)
Table 39. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
Table 41. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)
Table 43. Key Market Drivers & Growth Opportunities of Primary Sclerosing Cholangitis Treatment
Table 44. Key Market Challenges & Risks of Primary Sclerosing Cholangitis Treatment
Table 45. Key Industry Trends of Primary Sclerosing Cholangitis Treatment
Table 46. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 47. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share Forecast by Regions (2023-2028)
Table 48. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 49. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share Forecast by Type (2023-2028)
Table 50. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 51. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share Forecast by Application (2023-2028)
Table 52. Allergan Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 53. Allergan Primary Sclerosing Cholangitis Treatment Product Offered
Table 54. Allergan Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 55. Allergan Main Business
Table 56. Allergan Latest Developments
Table 57. Glenmark Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 58. Glenmark Primary Sclerosing Cholangitis Treatment Product Offered
Table 59. Glenmark Main Business
Table 60. Glenmark Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 61. Glenmark Latest Developments
Table 62. Impax Laboratories Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 63. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Offered
Table 64. Impax Laboratories Main Business
Table 65. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 66. Impax Laboratories Latest Developments
Table 67. Mylan Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 68. Mylan Primary Sclerosing Cholangitis Treatment Product Offered
Table 69. Mylan Main Business
Table 70. Mylan Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 71. Mylan Latest Developments
Table 72. Teva Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 73. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
Table 74. Teva Pharmaceuticals Main Business
Table 75. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 76. Teva Pharmaceuticals Latest Developments
Table 77. Dr. Falk Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 78. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Offered
Table 79. Dr. Falk Pharma Main Business
Table 80. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 81. Dr. Falk Pharma Latest Developments
Table 82. Daewoong Pharmaceutical Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 83. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Offered
Table 84. Daewoong Pharmaceutical Main Business
Table 85. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 86. Daewoong Pharmaceutical Latest Developments
Table 87. Epic Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 88. Epic Pharma Primary Sclerosing Cholangitis Treatment Product Offered
Table 89. Epic Pharma Main Business
Table 90. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 91. Epic Pharma Latest Developments
Table 92. Mitsubishi Tanabe Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 93. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Offered
Table 94. Mitsubishi Tanabe Pharma Main Business
Table 95. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 96. Mitsubishi Tanabe Pharma Latest Developments
Table 97. Lannett Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 98. Lannett Primary Sclerosing Cholangitis Treatment Product Offered
Table 99. Lannett Main Business
Table 100. Lannett Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 101. Lannett Latest Developments
Table 102. Bruschettini Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 103. Bruschettini Primary Sclerosing Cholangitis Treatment Product Offered
Table 104. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 105. Bruschettini Main Business
Table 106. Bruschettini Latest Developments
Table 107. Shanghai Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 108. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Offered
Table 109. Shanghai Pharma Main Business
Table 110. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 111. Shanghai Pharma Latest Developments
Table 112. Grindeks Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 113. Grindeks Primary Sclerosing Cholangitis Treatment Product Offered
Table 114. Grindeks Main Business
Table 115. Grindeks Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 116. Grindeks Latest Developments
Table 117. Acorda Therapeutics Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 118. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product Offered
Table 119. Acorda Therapeutics Main Business
Table 120. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 121. Acorda Therapeutics Latest Developments
Table 122. Gilead Sciences Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 123. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Offered
Table 124. Gilead Sciences Main Business
Table 125. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 126. Gilead Sciences Latest Developments
Table 127. Intercept Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 128. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
Table 129. Intercept Pharmaceuticals Main Business
Table 130. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 131. Intercept Pharmaceuticals Latest Developments
Table 132. Shire Plc Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 133. Shire Plc Primary Sclerosing Cholangitis Treatment Product Offered
Table 134. Shire Plc Main Business
Table 135. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 136. Shire Plc Latest Developments
Table 137. NGM Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 138. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
Table 139. NGM Biopharmaceuticals Main Business
Table 140. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 141. NGM Biopharmaceuticals Latest Developments
Table 142. Conatus Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 143. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
Table 144. Conatus Pharmaceuticals Main Business
Table 145. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 146. Conatus Pharmaceuticals Latest Developments
Table 147. Durect Corporation Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 148. Durect Corporation Primary Sclerosing Cholangitis Treatment Product Offered
Table 149. Durect Corporation Main Business
Table 150. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 151. Durect Corporation Latest Developments
Table 152. Sirnaomics Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 153. Sirnaomics Primary Sclerosing Cholangitis Treatment Product Offered
Table 154. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 155. Sirnaomics Main Business
Table 156. Sirnaomics Latest Developments
Table 157. Shenzhen HighTide Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
Table 158. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
Table 159. Shenzhen HighTide Biopharmaceuticals Main Business
Table 160. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 161. Shenzhen HighTide Biopharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Primary Sclerosing Cholangitis Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type in 2021
Figure 7. Primary Sclerosing Cholangitis Treatment in Hospital
Figure 8. Global Primary Sclerosing Cholangitis Treatment Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Primary Sclerosing Cholangitis Treatment in Clinics
Figure 10. Global Primary Sclerosing Cholangitis Treatment Market: Clinics (2017-2022) & ($ Millions)
Figure 11. Primary Sclerosing Cholangitis Treatment in Other
Figure 12. Global Primary Sclerosing Cholangitis Treatment Market: Other (2017-2022) & ($ Millions)
Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021
Figure 14. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Player in 2021
Figure 15. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Regions (2017-2022)
Figure 16. Americas Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 ($ Millions)
Figure 17. APAC Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 ($ Millions)
Figure 18. Europe Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 ($ Millions)
Figure 20. Americas Primary Sclerosing Cholangitis Treatment Value Market Share by Country in 2021
Figure 21. Americas Primary Sclerosing Cholangitis Treatment Consumption Market Share by Type in 2021
Figure 22. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021
Figure 23. United States Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region in 2021
Figure 28. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021
Figure 29. China Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 33. India Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Country in 2021
Figure 36. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type in 2021
Figure 37. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021
Figure 38. Germany Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 39. France Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021
Figure 46. Egypt Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 52. APAC Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 53. Europe Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 55. United States Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 56. Canada Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 57. Mexico Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 58. Brazil Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 59. China Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 60. Japan Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 61. Korea Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 63. India Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 64. Australia Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 65. Germany Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 66. France Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 67. UK Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 68. Italy Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 69. Russia Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 70. Spain Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 71. Egypt Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 72. South Africa Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 73. Israel Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 74. Turkey Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)
Figure 75. GCC Countries Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 ($ Millions)